These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 10855120)

  • 1. Anti-TNF alpha: new therapy for Crohn's disease.
    Mikula CA
    Gastroenterol Nurs; 1999; 22(6):245-8. PubMed ID: 10855120
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Review article: efficacy of infliximab in Crohn's disease--induction and maintenance of remission.
    Rutgeerts PJ
    Aliment Pharmacol Ther; 1999 Sep; 13 Suppl 4():9-15; discussion 38. PubMed ID: 10597334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Review article: the efficacy of infliximab in Crohn's disease--healing of fistulae.
    Present DH
    Aliment Pharmacol Ther; 1999 Sep; 13 Suppl 4():23-8; discussion 38. PubMed ID: 10597336
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Infliximab as disease-modifying therapy.
    D'Haens GR
    Eur J Gastroenterol Hepatol; 2003 Mar; 15(3):233-7. PubMed ID: 12610316
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Treatment of Crohn disease in adults with tumor necrosis factor-alpha (TNF-alpha) antibodies].
    Belaiche J; Louis E
    Rev Med Liege; 2000 Sep; 55(9):827-32. PubMed ID: 11105596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Infliximab: an updated review of its use in Crohn's disease and rheumatoid arthritis.
    Keating GM; Perry CM
    BioDrugs; 2002; 16(2):111-48. PubMed ID: 11985485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Infliximab (Remicade), a new biological treatment for Crohn's disease.
    D'Haens GR
    Ital J Gastroenterol Hepatol; 1999; 31(6):519-20. PubMed ID: 10575573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adalimumab for the treatment of Crohn's disease.
    Devlin SM; Panaccione R
    Expert Opin Biol Ther; 2008 Jul; 8(7):1011-9. PubMed ID: 18549330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibodies to tumour necrosis factor alpha as treatment for Crohn's disease.
    Bell S; Kamm MA
    Lancet; 2000 Mar; 355(9207):858-60. PubMed ID: 10752696
    [No Abstract]   [Full Text] [Related]  

  • 10. Monitoring functional serum antitumor necrosis factor antibody level in Crohn's disease patients who maintained and those who lost response to anti-TNF.
    Yamada A; Sono K; Hosoe N; Takada N; Suzuki Y
    Inflamm Bowel Dis; 2010 Nov; 16(11):1898-904. PubMed ID: 20310016
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial.
    D'haens G; Van Deventer S; Van Hogezand R; Chalmers D; Kothe C; Baert F; Braakman T; Schaible T; Geboes K; Rutgeerts P
    Gastroenterology; 1999 May; 116(5):1029-34. PubMed ID: 10220494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of treatment with chimeric monoclonal antibody (Infliximab) to tumor necrosis factor-alpha for Crohn's disease in Japan: evaluation by rapid turnover proteins, and radiologic and endoscopic findings.
    Asakura H; Yao T; Matsui T; Koganei K; Fukushima T; Takazoe M; Hobara R; Nakano H; Okamura S; Matsueda K; Kashida H; Makiyama K; Hiwatashi N; Kashiwagi K; Hibi T
    J Gastroenterol Hepatol; 2001 Jul; 16(7):763-9. PubMed ID: 11446884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Infliximab: mechanism of action beyond TNF-alpha neutralization in inflammatory bowel disease.
    Kirman I; Whelan RL; Nielsen OH
    Eur J Gastroenterol Hepatol; 2004 Jul; 16(7):639-41. PubMed ID: 15201575
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Treatment of Crohn's disease with anti TNF alpha antibodies--the experience in the Tel Aviv Medical Center].
    Dotan I; Yeshurun D; Hallak A; Horowitz N; Tiomny E; Reif S; Halpern Z; Rachmilewitz D
    Harefuah; 2001 Apr; 140(4):289-93, 368. PubMed ID: 11303390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High serum tumor necrosis factor-alpha levels are associated with lack of response to infliximab in fistulizing Crohn's disease.
    Martínez-Borra J; López-Larrea C; González S; Fuentes D; Dieguez A; Deschamps EM; Pérez-Pariente JM; López-Vázquez A; de Francisco R; Rodrigo L
    Am J Gastroenterol; 2002 Sep; 97(9):2350-6. PubMed ID: 12358255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transcending conventional therapies: the role of biologic and other novel therapies.
    Sandborn WJ
    Inflamm Bowel Dis; 2001 May; 7 Suppl 1():S9-16. PubMed ID: 11380043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-TNF therapy for Crohn's disease: a perspective (infliximab is not the drug we have been waiting for).
    Shanahan F
    Inflamm Bowel Dis; 2000 May; 6(2):137-9. PubMed ID: 10833074
    [No Abstract]   [Full Text] [Related]  

  • 18. Prediction of antitumour necrosis factor clinical efficacy by real-time visualisation of apoptosis in patients with Crohn's disease.
    Van den Brande JM; Koehler TC; Zelinkova Z; Bennink RJ; te Velde AA; ten Cate FJ; van Deventer SJ; Peppelenbosch MP; Hommes DW
    Gut; 2007 Apr; 56(4):509-17. PubMed ID: 17082252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TNF-alpha antagonists for the treatment of Crohn's disease.
    Kam LY; Targan SR
    Expert Opin Pharmacother; 2000 May; 1(4):615-22. PubMed ID: 11249506
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Review article: targeting TNF alpha as a key cytokine in the inflammatory processes of Crohn's disease--the mechanisms of action of infliximab.
    van Deventer SJ
    Aliment Pharmacol Ther; 1999 Sep; 13 Suppl 4():3-8; discussion 38. PubMed ID: 10597333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.